IP Library Granted Patent US 11,357,751
Granted Patent B2
US 11,357,751 · App. 16/304,248 · Granted Jun 14, 2022

Composition for preventing or mitigating dementia

Inventors: Kah Hay Yuen (Ipoh, MY); David Sue San Ho (Ipoh, MY); Jia Woei Wong (Ipoh, MY)
Assignee: Attest Research Sdn Bhd
A61K31/355A61K31/01A61K31/519A61K31/675A61K31/714
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,357,751
App. No.
16/304,248
Granted
Jun 14, 2022
Kind
B2
Abstract

The present invention provides a composition for preventing or mitigating dementia in a subject comprising a mixture of tocotrienols, tocopherol, squalene and B vitamin, and a pharmaceutically acceptable carrier.

Claims (14)

1. A composition for preventing or mitigating dementia in a brain of a subject, comprising:

alpha-tocotrienol in an amount ranging from 4% to 11% by weight of the composition;

beta-tocotrienol in an amount ranging from 0.25% to 2% by weight of the composition;

gamma-tocotrienol in an amount ranging from 7% to 15% by weight of the composition;

delta-tocotrienol in an amount ranging from 2.0% to 7% by weight of the composition;

alpha-tocopherol in an amount ranging from 3% to 9% by weight of the composition;

squalene in an amount ranging from 1.0% to 5.0% by weight of the composition;

vitamin B6 in an amount ranging from 1.0% to 1.5% by weight of the composition;

vitamin B9 in an amount ranging from 0.04% to 0.06% by weight of the composition;

vitamin B12 in an amount ranging from 0.03% to 0.05% by weight of the composition; and

a pharmaceutically acceptable carrier in an amount ranging from 40% to 70% by weight of the composition;

wherein administration of the composition reduces or prevents white matter lesions in the brain of the subject.

2. The composition according to claim 1 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of beeswax, butylated hydroxytoluene, plant-based oil, caprylocaproyl macrogolglycerides, polyoxyethylene castor oil or derivatives, polysorbate, polyglycerol esters of fatty acids, sucrose esters of fatty acids, polyethylene alkyl esters, polyoxyl 40 stearate, phospholipids and combinations thereof.

3. The composition according to claim 1 , wherein the squalene is derived from a plant material.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2019
From: YUEN, KAH HAY; HO, DAVID SUE SAN; WONG, JIA WOEI
To: ATTEST RESEARCH SDN BHD
Reel/Frame 048383/0001 →
Priority Claims (1)
MY PI 2016701846 · May 23, 2016 · national
Continuity (1)
Related Publication 20200316017A1 · Oct 8, 2020